CytoSorbents Corporation Forecast, price target & analysts
CytoSorbents Corporation Target price 2026 - Analyst rating & recommendation
CytoSorbents Corporation Classifications & Recommendation:
CytoSorbents Corporation Price Target
| Target Price | $5.48 |
| Price | $0.66 |
| Potential |
736.00%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target CytoSorbents Corporation 2027 .
The average CytoSorbents Corporation target price is $5.48.
This is
736.00%
register free of charge
$10.50
1,501.10%
register free of charge
$0.76
15.51%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend CytoSorbents Corporation to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CytoSorbents Corporation stock has an average upside potential 2027 of
736.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 35.59 | 38.18 |
| 14.47% | 7.27% | |
| EBITDA Margin | -41.81% | -29.53% |
| 56.42% | 29.37% | |
| Net Margin | -58.22% | -25.16% |
| 38.12% | 56.78% |
5 Analysts have issued a sales forecast CytoSorbents Corporation 2025 . The average CytoSorbents Corporation sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an CytoSorbents Corporation EBITDA forecast 2025. The average CytoSorbents Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 CytoSorbents Corporation Analysts have issued a net profit forecast 2025. The average CytoSorbents Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.38 | -0.15 |
| 41.54% | 60.53% | |
| P/E | negative | |
| EV/Sales | 1.26 |
5 Analysts have issued a CytoSorbents Corporation forecast for earnings per share. The average CytoSorbents Corporation EPS is
This results in the following potential growth metrics and future valuations:
CytoSorbents Corporation...
Current CytoSorbents Corporation Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Dec 16 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Nov 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 14 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Dec 16 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Nov 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 14 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 20 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jul 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
